Korean J Urol.  2011 Apr;52(4):260-264.

Long-Term Follow-Up Results of Photoselective Vaporization of the Prostate with the 120 W Greenlight HPS Laser for Treatment of Benign Prostatic Hyperplasia

• Kang SH
• Choi YS
• Kim SJ
• Cho HJ
• Hong SH
• Lee JY
• Hwang TK
• Kim SW

Abstract

PURPOSE
With the use of 12 months of follow-up data, this study was conducted to evaluate the efficacy of photoselective vaporization of the prostate (PVP) with the 120 W Greenlight high performance system (HPS) laser for the treatment of symptomatic benign prostatic hyperplasia.
MATERIALS AND METHODS
Data were collected from 104 patients who were diagnosed with benign prostatic hyperplasia and who underwent PVP with the 120 W Greenlight HPS Laser. Postoperative parameters, including International Prostate Symptom Score (IPSS), quality of life (QoL) score, maximum urinary flow rate (Qmax), and postvoid residual volume (PVR), were assessed and compared with preoperative baseline values.
RESULTS
The mean age of the patients was 71.1+/-7.7. The baseline mean prostate-specific antigen level was 3.8+/-2.7 ng/ml, the mean prostate size was 43.9+/-20.6 g, the mean preoperative IPSS was 18.4+/-8.5, the mean QoL score was 4.1+/-1.0, the mean Qmax was 9.9+/-5.5 ml/sec, and the mean PVR was 89.6+/-207.1 ml. During surgery, the mean operation time was 21.8+/-11.3 minutes, the mean lasing time was 16.9+/-10.5 minutes, and the mean total applied energy was 170,068+/-63,181 J. At 1 month, significant improvements were observed in total IPSS (11.5+/-6.7, p<0.05), voiding symptom score (6.1+/-5.4, p<0.05), and QoL score (2.2+/-1.5, p<0.05); however, there were no significant improvements in storage symptom score (4.8+/-3.8, p=0.06), Qmax (12.6+/-10.2, p=0.06), and PVR (40.1+/-30.5, p=0.41). However, 3 months after surgery, all postoperative follow-up parameters showed significant improvements, and the 6- and 12-month data showed sustained improvement of postoperative follow-up parameters.
CONCLUSIONS
Significant improvements were observed in subjective and objective voiding parameters, which were evident at 3 months after PVP and were sustained throughout a period of 12 months after PVP.

Keyword

Laser vaporization; Prostatic hyperplasia; Transurethral prostatectomy

MeSH Terms

Follow-Up Studies
Humans
Laser Therapy
Prostate
Prostate-Specific Antigen
Prostatic Hyperplasia
Quality of Life
Residual Volume
Transurethral Resection of Prostate
Volatilization
Prostate-Specific Antigen

Figure

• 

  FIG. 1 Changes in preoperative and postoperative IPSS scores. IPSS: International Prostate Symptom Score, Preop: preoperative characteristics, PVP: photoselective vaporization of prostate, QoL: quality of life, a: p<0.05 compared with preoperative IPSS scores.

• 

  FIG. 2 (A) Preoperative and postoperative values of Qmax. (B) Preoperative and postoperative PVR. Qmax: maximum urinary flow rate, PVR: postvoid residual volume, Preop: preoperative, Postop: postoperative.

Reference

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984. 132:474–479.

2. Levy A, Samraj GP. Benign prostatic hyperplasia: when to "watch and wait," when and how to treat. Cleve Clin J Med. 2007. 74:Suppl 3. S15–S20.

3. de la Rosette JJ, Alivizatos G, Madersbacher S, Perachino M, Thomas D, Desgrandchamps F, et al. EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol. 2001. 40:256–263.

4. Roehrborn CG, Bartsch G, Kirby R, Andriole G, Boyle P, de la Rosette J, et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology. 2001. 58:642–650.

5. Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP. Immediate and postoperative complications of transurethral prostatectomy in the 1990s. J Urol. 1999. 162:1307–1310.

6. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol. 2006. 50:969–979.

7. Reich O, Gratzke C, Stief CG. Techniques and long-term results of surgical procedures for BPH. Eur Urol. 2006. 49:970–978.

8. Te AE. The development of laser prostatectomy. BJU Int. 2004. 93:262–265.

9. Bachmann A, Ruszat R, Wyler S, Reich O, Seifert HH, Müller A, et al. Photoselective vaporization of the prostate: the basel experience after 108 procedures. Eur Urol. 2005. 47:798–804.

10. Malek RS, Kuntzman RS, Barrett DM. Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol. 2005. 174:1344–1348.

11. Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA, et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol. 2004. 172:1404–1408.

12. Malek RS, Kuntzman RS, Barrett DM. High power potassium-titanyl-phosphate laser vaporization prostatectomy. J Urol. 2000. 163:1730–1733.

13. Spaliviero M, Araki M, Wong C. Short-term outcomes of Greenlight HPS laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH). J Endourol. 2008. 22:2341–2347.

14. Ruszat R, Seitz M, Wyler SF, Müller G, Rieken M, Bonkat G, et al. Prospective single-centre comparison of 120-W diode-pumped solid-state high-intensity system laser vaporization of the prostate and 200-W high-intensive diode-laser ablation of the prostate for treating benign prostatic hyperplasia. BJU Int. 2009. 104:820–825.

15. Malek RS, Barrett DM, Kuntzman RS. High-power potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 hours later. Urology. 1998. 51:254–256.

16. Bouchier-Hayes DM, Van Appledorn S, Bugeja P, Crowe H, Challacombe B, Costello AJ. A randomized trial of photoselective vaporization of the prostate using the 80-W potassium-titanyl-phosphate laser vs transurethral prostatectomy, with a 1-year follow-up. BJU Int. 2010. 105:964–969.

17. Ruszat R, Wyler S, Forster T, Reich O, Stief CG, Gasser TC, et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol. 2007. 51:1031–1038.

18. Sandhu JS, Ng CK, Gonzalez RR, Kaplan SA, Te AE. Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol. 2005. 19:1196–1198.

19. Ruszat R, Seitz M, Wyler SF, Abe C, Rieken M, Reich O, et al. GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol. 2008. 54:893–901.

20. Choo SH, Han DH, Lee SW. The efficacy and safety of KTP photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: the 2-year results. Korean J Urol. 2008. 49:831–836.

21. Al-Ansari A, Younes N, Sampige VP, Al-Rumaihi K, Ghafouri A, Gul T, et al. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol. 2010. 58:349–355.

22. Son H, Ro YK, Min SH, Choo MS, Kim JK, Lee CJ. Modified vaporization-resection for photoselective vaporization of the prostate using a GreenLight high-performance system 120-W Laser: the Seoul technique. Urology. 2011. 77:427–432.

23. Ko DW, Jeong BC, Son H. Initial experiences with a new 120 W Greenlight™ high-power system for photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia in Korea. Korean J Urol. 2009. 50:1089–1094.

24. Ahmed HU, Thwaini A, Shergill IS, Hammadeh MY, Arya M, Kaisary AV. Greenlight prostatectomy: a challenge to the gold standard? A review of KTP photoselective vaporization of the prostate. Surg Laparosc Endosc Percutan Tech. 2007. 17:156–163.

25. Heinrich E, Wendt-Nordahl G, Honeck P, Alken P, Knoll T, Michel MS, et al. 120W Lithium triborate laser for photoselective vaporization of the prostate: comparison with 80w potassium-titanyl-phosphate laser in an ex-vivo model. J Endourol. 2010. 24:75–79.

26. Reich O, Bachmann A, Siebels M, Hofstetter A, Stief CG, Sulser T. High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol. 2005. 173:158–160.